"A year earlier, AstraZeneca acquired Pearl Therapeutics for up to $1.15 billion after the private, California-based company raised $232 million over six years to take a repurposed generic to late-stage trial for the treatment of COPD."
AstraZeneca then completed Phase 3 clinical trials.
"AstraZeneca's potential chronic obstructive pulmonary disease treatment improved lung function in patients during two Phase III clinical trials, the company announced.
The Pinnacle studies marks the first Phase III outcomes from a series of pipeline candidates under development by AstraZeneca using technology developed by Pearl Therapeutics. AstraZeneca acquired Pearl, a developer of small-molecule drugs for respiratory diseases, in 2013."
"Chris Yochim, a former head of external relations for AstraZeneca and the current chairman of the Delaware BioScience Association, said Invion is well positioned to follow suit.
IVX Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)